Form 4: Adaptive Bio CEO Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies CEO Chad M. Robins sold 160,734 shares of common stock in late 2025 through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), reported sales of common stock.
• On November 26, 2025, Robins sold 35,736 shares at a weighted average price of $19.68 per share, with prices ranging from $19.43 to $20.29.
• On December 1, 2025, Robins sold an additional 124,998 shares at a weighted average price of $18.94 per share, with prices ranging from $18.78 to $19.20.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 11, 2025.
• Following these sales, Robins beneficially owns 2,709,241 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider stock sales executed under a pre-arranged 10b5-1 plan, which typically carries a neutral sentiment as it's not indicative of new positive or negative company developments.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were scheduled in advance and not based on immediate, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

Industry Context

This filing, a Form 4, reports an individual insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• Sales of common stock by the CEO and Chairman, Chad M. Robins, to the open market.

Stakeholder Impact

• Shareholders: May observe a reduction in the CEO's direct equity ownership, though this is mitigated by the pre-arranged nature of the 10b5-1 plan.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Chad M. Robins, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Director